Forty @entity1 with previously untreated @entity43 ( @entity43 ), with FIGO stages Ic-IV, were randomly allocated to receive intravenously either @entity3003 (C) 400 mg/m2 every three weeks (C arm, 20 @entity1 ) or a combination of C 350 mg/m2, @entity1260 (I) 5 g/m2 with mesna every three weeks, @entity1891 (V) 1.4 mg/m2 (maximum total dose 2 mg) and @entity1732 (B) 30 mg every ten days (CIVB arm, 20 @entity1 ). Responding @entity1 received 6 courses of chemotherapy and all 40 @entity1 were evaluable for @entity137 , response and survival. Clinical characteristics of @entity1 were similar in both arms. Clinico-imaging results with chemotherapy were as follows: in C arm, @entity30480 (55%) and partial remission (cPR) five (25%) @entity1 for an overall response rate (ORR) 80%. For CIVB arm, cCR ten (50%) and cPR four (20%) @entity1 for an ORR 70%. Second look operation (SLO) was performed in three of the 11 cCR @entity1 in the C arm and six of the ten cCR @entity1 in the CIVB arm. Pathological CR (pCR) was confirmed in two of the three cCR C arm @entity1 and two of the six in the CIVB @entity1 . In the first interim analysis statistically significant differences, all favoring monochemotherapy, were seen in response duration, time to progression, disease-free and overall survival. These results along with the severe myelotoxicity resulting in dose reductions in the CIVB @entity1 led us to stop enrolling new @entity1 and follow this population closely for long-term results. These confirmed the first observations of the superiority of single-agent @entity3003 in response duration (p = 0.034), time to progression (p = 0.028), disease-free survival (p = 0.010) and overall survival (p = 0.043). Because of the above reasons we have concluded that monochemotherapy with @entity3003 is to be preferred over @entity3003 in combination with other drugs.

Superiority of @entity3003 monochemotherapy over @entity3003 -based polychemotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['OC', 'epithelial ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity30480 :: ('51554', 'Gene') :: ['clinical complete remission (cCR) 11'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
